ViiV Healthcare Cabenuva (cabotegravir + rilpivirine) achieved superior rates of viral suppression compared with standard-of-care oral antiretroviral therapy (ART) at six months in the phase IIIb CROWN study, according to a GSK news report from London on 6 October 2026. GSK plc (LSE/NYSE: GSK) said ViiV Healthcare, the global specialist HIV company majority owned by GSK with Shionogi as a shareholder, announced that the trial met its primary endpoint. Participants were adults and adolescents living with HIV-1 who had detectable virus when they entered the study.
CROWN is described as the first large, international phase IIIb trial to evaluate the investigational use of long-acting Cabenuva against daily oral therapy in people with a history of antiretroviral treatment and unsuppressed HIV. The regimen, abbreviated CAB + RPV LA, is administered six times a year. For people who face challenges achieving or maintaining viral suppression on daily pills, the ViiV Healthcare Cabenuva result adds to the body of data on long-acting cabotegravir plus rilpivirine.
The announcement carries an important qualifier. Use of CAB + RPV LA in people with detectable viremia is investigational and has not been approved by regulatory authorities. The company said the data will be shared with health authorities for regulatory review, but no filing date or timeline was disclosed. This ViiV Healthcare Cabenuva update therefore describes trial results, not a label change.
ViiV Healthcare Cabenuva CROWN Study Design and Enrollment
The ViiV Healthcare Cabenuva CROWN study is an international, randomised, open-label trial. It was designed to test whether people living with HIV-1 who have detectable virus despite a history of daily oral ART can directly initiate CAB + RPV LA and achieve viral suppression. The announcement states that the study enrolled approximately 326 participants, including adults and adolescents, across eight countries at 85 study sites.
Entry criteria centred on resistance. Participants had detectable virus at study entry and no evidence of resistance to INSTIs (integrase inhibitors) or NNRTIs (non-nucleoside reverse transcriptase inhibitors). The regimen pairs one drug from each of those classes, so the design tests direct initiation in people who remain viremic but show no resistance to the classes involved.
The comparator was standard-of-care oral ART, and the primary endpoint was superior viral suppression at six months. GSK did not publish suppression percentages, the size of the treatment difference, safety findings or discontinuation rates in the announcement. Those items are marked as not disclosed in the table below, and the ViiV Healthcare Cabenuva dataset should be reviewed closely once full results appear.
CROWN Study Key Facts
| Parameter | Detail |
|---|---|
| Study name | CROWN |
| Phase | IIIb |
| Design | International, randomised, open-label |
| Investigational regimen | CAB + RPV LA (Cabenuva), administered six times a year |
| Comparator | Standard-of-care oral antiretroviral therapy |
| Population | Adults and adolescents with HIV-1, detectable virus at entry, prior ART history |
| Resistance criteria | No evidence of INSTI or NNRTI resistance |
| Enrollment | Approximately 326 participants |
| Countries / sites | Eight countries / 85 study sites |
| Primary endpoint result | Met: superior viral suppression at six months |
| Suppression rates (%) | Not disclosed |
| Safety data | Not disclosed |
| Regulatory status of this use | Investigational, not approved |
ViiV Healthcare Cabenuva Builds on the LATITUDE Study Evidence
The CROWN findings build on the LATITUDE study. According to GSK, LATITUDE showed that CAB + RPV LA was superior to daily oral therapy in maintaining viral suppression among people with HIV. Those participants had already achieved suppression on oral ART but had a history of adherence challenges.
CROWN differs in who it enrolled. Rather than maintaining suppression, it asked whether the regimen could be started directly in people who still had detectable virus. The company says this addresses a remaining evidence gap. It also says the ViiV Healthcare Cabenuva data extend support for long-acting cabotegravir plus rilpivirine across treatment-experienced populations, including people with viremia at initiation, under investigational use.
Jean van Wyk, MBChB, MFPM, Chief Medical Officer at ViiV Healthcare, said the study was designed to fill an “important evidence gap.” He added that the findings give insight into the potential role of this approach for treatment-experienced people living with HIV. He also noted that significant barriers to optimising care with daily oral therapy continue to exist.
LATITUDE and CROWN Compared (as described by GSK)
| Feature | LATITUDE | CROWN |
|---|---|---|
| Regimen | CAB + RPV LA | CAB + RPV LA |
| Comparator | Daily oral therapy | Standard-of-care oral ART |
| Population | Suppressed on oral ART, history of adherence challenges | Detectable virus at entry, history of ART |
| Question tested | Maintaining viral suppression | Direct initiation and achieving viral suppression |
| Reported outcome | CAB + RPV LA superior to daily oral therapy | Primary endpoint met: superior suppression at six months |
ViiV Healthcare Cabenuva Indication, Approvals and Mechanism of Action
Under current labelling, Cabenuva is indicated as a complete regimen for HIV-1 infection in adults and adolescents 12 years and older weighing at least 35 kg. It replaces the current antiretroviral regimen in people who are virologically suppressed (HIV-1 RNA <50 c/ml) on a stable regimen. They must have no history of treatment failure and no known or suspected resistance to cabotegravir or rilpivirine. The CROWN population, viremic at entry, falls outside that approved indication.
CAB + RPV LA is approved in the US and other markets as Cabenuva, and as Vocabria + Rekambys in the EU and Japan, for the suppressed population described above. The ViiV Healthcare Cabenuva regimen combines cabotegravir, an integrase strand transfer inhibitor (INSTI) developed by ViiV Healthcare, with rilpivirine, an NNRTI developed by Johnson & Johnson.
INSTIs inhibit HIV replication by preventing viral DNA from integrating into the genetic material of human immune cells called T-cells. This step is essential to the replication cycle and to establishing chronic disease. Rilpivirine interferes with an enzyme called reverse transcriptase, which stops the virus from multiplying. In the US, rilpivirine tablets used with cabotegravir are indicated for short-term treatment in the same suppressed population. GSK directs readers to the full Prescribing Information.
Cabenuva Regimen Components and Labelling
| Item | Detail |
|---|---|
| Brand names | Cabenuva (US and other markets); Vocabria + Rekambys (EU and Japan) |
| Component 1 | Cabotegravir, INSTI, developed by ViiV Healthcare |
| Component 2 | Rilpivirine, NNRTI, developed by Johnson & Johnson |
| Approved population | Adults and adolescents 12 years and older, at least 35 kg, virologically suppressed (HIV-1 RNA <50 c/ml) |
| Approval conditions | Stable regimen, no treatment failure history, no known or suspected cabotegravir or rilpivirine resistance |
| Dosing frequency in CROWN | Six times a year |
| Use in viremia | Investigational, not approved |
What the ViiV Healthcare Cabenuva CROWN Result Means Next
ViiV Healthcare said data will be shared with health authorities for regulatory review, and that full results are planned for presentation at an upcoming scientific meeting. Neither the meeting nor the submission timing was named. Until the full dataset is public, the ViiV Healthcare Cabenuva result in viremic patients remains a topline announcement from the sponsor.
ViiV Healthcare was established in November 2009, with GSK and Shionogi as current shareholders. The company describes itself as dedicated to advances in HIV treatment and care, and to prevention for people who could benefit from it. GSK describes itself as a global biopharma company that aims to unite science, technology and talent to get ahead of disease together.
GSK cautions that forward-looking statements, including those in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially. It points to the risk factors in its 2025 Annual Report on Form 20-F and its Q2 2026 results. Statements about regulatory review should be read accordingly. Anyone weighing the ViiV Healthcare Cabenuva findings should consult the full Prescribing Information and a qualified clinician.
